Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
08:05am, Friday, 22'nd Aug 2025
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
Exact Sciences to Participate in September Investor Conferences
06:00am, Tuesday, 19'th Aug 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
09:30am, Tuesday, 12'th Aug 2025
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:07am, Monday, 11'th Aug 2025
Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value investor. The Ark Invest co-founder, CEO, and chief investment officer is often a
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
10:46am, Monday, 11'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 3 Health Care Stocks That Are Preparing To Pump This Month
08:01am, Monday, 11'th Aug 2025
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
02:56pm, Thursday, 07'th Aug 2025
Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 07'th Aug 2025
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript
11:11pm, Wednesday, 06'th Aug 2025
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Inves
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
07:16pm, Wednesday, 06'th Aug 2025
Exact Sciences (EXAS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.09 per share a year ago.
Exact Sciences (EXAS) Q2 Revenue Up 16%
05:13pm, Wednesday, 06'th Aug 2025
Exact Sciences (EXAS) Q2 Revenue Up 16%
Exact Sciences Announces Second Quarter 2025 Results
04:05pm, Wednesday, 06'th Aug 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
07:00am, Thursday, 31'st Jul 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ac
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 30'th Jul 2025
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more att
